M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparison of Endobronchial Ultrasound-Guided Biopsy Using Fine Needle Aspiration Versus Fine Needle Capillary Sampling

Not Applicable

Completed

Conditions: Lymphadenopathy

Interventions: Procedure: Lymph Node Needle Tissue Collections

First Posted Date: 2009-04-23

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00886847

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Phase 2

Completed

Conditions: Brain Cancer
Pediatric Cancers

Interventions: Drug: Bevacizumab
Drug: Lapatinib

First Posted Date: 2009-04-20

Last Posted Date: 2020-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00883688

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 3 locations

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Gemtuzumab ozogamicin

First Posted Date: 2009-04-16

Last Posted Date: 2013-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT00882102

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Automated Pain Intervention for Underserved Minority Breast Cancer Patients

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaires
Behavioral: Telephone Intervention

First Posted Date: 2009-04-14

Last Posted Date: 2019-04-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00881010

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Phase 1

Completed

Conditions: Follicular Lymphoma
Mantle Cell Lymphoma
CD20 Positive
Chronic Lymphocytic Leukemia
Marginal Zone Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Anti-Thymocyte Globulin
Drug: Bendamustine
Biological: Filgrastim
Drug: Fludarabine
Drug: Methotrexate
Biological: Rituximab
Drug: Tacrolimus

First Posted Date: 2009-04-14

Last Posted Date: 2019-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00880815

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Malignant Neoplasm

Interventions: Drug: Fluorothymidine F-18
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2009-04-13

Last Posted Date: 2023-06-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00880074

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Prostate Conformal Cryotherapy

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Procedure: Cryoablation

First Posted Date: 2009-04-08

Last Posted Date: 2018-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00877682

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Quality of Life in Men With High Risk Localized Prostate Cancer

Withdrawn

Conditions: Prostate Cancer

Interventions: Behavioral: QOL Questionnaire

First Posted Date: 2009-04-08

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00877617

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: A Qualitative Study

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: Interview

First Posted Date: 2009-04-08

Last Posted Date: 2011-09-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00878267

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Phase 1

Terminated

Conditions: Advanced Cancers

Interventions: Drug: Temsirolimus

First Posted Date: 2009-04-08

Last Posted Date: 2016-08-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT00877773

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy